publication date: Oct. 30, 2014

Zytiga and Prednisone Extends Overall Survival in mCRPC Trial

 

A final analysis of a phase III trial showed that Zytiga (abiraterone acetate) plus prednisone significantly prolonged overall survival compared to an active control of placebo plus prednisone, in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.

The study demonstrated a 19 percent reduction in risk of death in this study population, with a median OS of 34.7 compared to 30.3 months respectively (HR= 0.81 [95% CI, 0.70-0.93]; p = 0.0033), after a median follow-up of more than four years (49.2 months).

“OS is particularly noteworthy in [the study], because 67 percent of men in the Zytiga plus prednisone arm and 80 percent in the control arm received subsequent therapy,” said Charles Ryan, professor of clinical medicine and urology at the University of California, San Francisco, and lead investigator of the study, COU-AA-302. “This includes 44 percent of men in the control arm who subsequently received Zytiga plus prednisone. The use of subsequent therapies did not impact the statistical significance between the Zytiga and control arms, and makes these results all the more compelling after adjusting for the crossover effect.”

In addition, the final analysis demonstrated a significant improvement in median time to opiate use for cancer-related pain compared to placebo plus prednisone, a median 33.4 months vs. 23.4 months respectively (HR= 0.72 [95% CI, 0.61-0.85]; p = 0.0001).

COU-AA-302 is an international, randomized, double-blind, placebo controlled study that included 1,088 men with mCRPC who had not received prior chemotherapy, and … Continue reading CCL Oct – Prostate Cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.